SBIA: Tomorrow - Drug Master File (DMF) and Drug Substance Question and Answer Webinar Following March 3-4, 2021 Workshop

FDA | CDER | Small Business and Industry Assistance WEBINARS Drug Master File (DMF) and Drug Substance Question and Answer Webinar Following March 3-4, 2021 Workshop April 9, 2021 | 1:00 - 4:00 p.m. Eastern This webinar is FREE. Register This follow-on webinar will focus on answering attendee questions regarding the posters and presentations given at the Drug Master File (DMF) and Drug Substance Workshop on March 3-4, 2021. There will be an opportunity for live questions and panel discussion with subject matter experts. TOPICS Information on submitting and managing DMFs, fee payments, and facility identification How to maximize communication tools offered by the agency to get answers to your questions What to consider for development of a complex API Process validation and ICH Q7 How to select an appropriate regulatory starting material (ICH Q11 and Q11 Q&A) Expectations for impurity assessment ((Q)SAR & pharm-tox) and control (ICH Q3A, Q3C, Q3D, and M7) How to develop a robust chromatographic method for API release Expectations for Lifecycle Management of DMFs and the Draft Post-Approval Change Guidance Common mistakes and how to avoid them: case study examples Posters covering topics of interest AUDIENCE Participants of SBIA-DMF/Drug Substance Workshop of March 3 and 4, 2021. Manufacturers of active pharmaceutical ingredients in support of an ANDA or NDA (AAM, APIC, PhRMA, EFPAI, JPMA, DIA) Regulatory affairs professional or agents Outside testing facilities that provide data to support the safety (AMES Studies, (Q)SAR predictions, nitrosamine testing to support risk assessment) or quality (release or stability testers) of the active pharmaceutical ingredient in a DMF Outside manufacturing facilities that provide intermediates to be used in the manufacture of active pharmaceutical ingredients. CONTINUING EDUCATION Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations.  Certificates are only available during the two weeks post-event. This course: has been pre-approved by RAPS as eligible for credits (appropriate to real-time attendance) towards a participant's RAC recertification upon full completion. has been pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area. has been pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant's RQAP re-registration. has been approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material. The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry. Register for Upcoming Training Watch Learning Library Recordings on YouTube Subscribe to CDER SBIA Email Updates Follow on LinkedIn Follow on Twitter

This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.   SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA